Lipopolysaccharide neutralization by the antibacterial peptide CM4

Area of Science:

• Microbiology
• Immunology
• Pharmacology

Background:

• Lipopolysaccharide (LPS) from Gram-negative bacteria triggers inflammatory responses and can cause septic shock.
• Developing molecules with anti-endotoxin properties is crucial for managing severe bacterial infections.
• The CD14+ murine macrophage cell line RAW264.7 is a key model for studying LPS-induced inflammation.

Purpose of the Study:

• To evaluate the efficacy of antibacterial peptide CM4 in binding Escherichia coli LPS.
• To determine if CM4 can inhibit LPS-induced inflammatory responses in RAW264.7 cells.
• To explore CM4's potential as a therapeutic agent against endotoxin shock.

Main Methods:

• Limulus amoebocyte lysate assay to confirm LPS binding.
• Assessing inhibition of CM4's antibacterial activity by LPS.
• Flow cytometry to analyze FITC-conjugated LPS binding to RAW264.7 cells.
• Measuring TNF-alpha and IL-6 mRNA expression and cytokine/NO release.

Main Results:

• CM4 demonstrated avid binding to E. coli LPS.
• LPS inhibited CM4's antibacterial activity, confirming high affinity.
• CM4 blocked LPS binding to RAW264.7 cells.
• CM4 suppressed LPS-induced TNF-alpha and IL-6 expression and release.

Conclusions:

• Antibacterial peptide CM4 binds strongly to LPS.
• CM4 inhibits LPS-induced inflammatory cytokine production by blocking LPS-CD14 interaction.
• CM4 shows potential therapeutic value in preventing endotoxin shock.